Target ALS

NeuroDex is a biotechnology company developing blood-based diagnostics for neurodegenerative diseases, leveraging proprietary neuron-derived exosome isolation technology to enable early detection, patient stratification, and disease monitoring. The platform isolates vesicles from neurons, oligodendrocytes, and glial cells from a standard blood sample, providing a window into brain pathology across multiple neurological indications. The approach supports the development of disease-modifying therapies, with Alzheimer's disease highlighted as a leading application. Founded in 2018 and based in Arlington, Massachusetts, NeuroDex collaborates with life sciences companies and academic partners to translate research into clinically actionable diagnostics.

Mabylon AG, a Swiss biotechnology company, specializes in discovering and developing therapies derived from naturally occurring human antibodies. It uses advanced B-cell screening technologies and serum antibody reactivity screens on large human populations to identify rare, disease-targeting antibodies. Mabylon's lead programs include MY006 for peanut allergy, shown to prevent anaphylaxis in mouse models, and a TDP-43 targeting antibody for ALS/FTLD, partnered with SciNeuro Pharmaceuticals.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.